2021
Identification of Cellular Damage in Uteri From Hyperinsulinemic Mice Treated With Unopposed Estradiol
Kelly K, Huang J, Joshi A, Tal A, Wong S, Flannery C. Identification of Cellular Damage in Uteri From Hyperinsulinemic Mice Treated With Unopposed Estradiol. Journal Of The Endocrine Society 2021, 5: a750-a751. DOI: 10.1210/jendso/bvab048.1526.Peer-Reviewed Original ResearchUnopposed estradiolWT miceMKR miceEndometrial adenocarcinomaNuclear atypiaExact testPlacebo-treated miceSetting of hyperinsulinemiaInsulin tolerance testingNormal-weight womenSetting of obesityEffects of estradiolCohort of miceFischer's exact testLower body weightOxidative stress-induced damagePercent body fatDNA damageBlinded histological analysisPartial hysterectomyWeight womenAnovulatory cyclesEndometrial glandsHyperinsulinemic miceCystic dilation
2018
Postmenopausal Women with Endometrial Cancer Have Greater Metabolic Dysfunction and Higher BMI than Women with Benign Endometrium
COOKE K, DUN E, ANAM A, FLANNERY C. Postmenopausal Women with Endometrial Cancer Have Greater Metabolic Dysfunction and Higher BMI than Women with Benign Endometrium. Diabetes 2018, 67 DOI: 10.2337/db18-302-lb.Peer-Reviewed Original ResearchEndometrial adenocarcinomaType 2 diabetesBenign hyperplasiaPostmenopausal womenBMI distributionEC pathogenesisMore premenopausal womenRole of obesityIndependent risk factorWomen age 50T-testStudent's t-testBMI 25Premenopausal womenLow HDLObese womenEndometrial cancerHigh triglyceridesTotal cholesterolHigher BMIMetabolic abnormalitiesProspective studyBenign endometriumMedical recordsRisk factors
2016
Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium
Flannery CA, Fleming AG, Choe GH, Naqvi H, Zhang M, Sharma A, Taylor HS. Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium. Endocrinology 2016, 157: 3699-3708. PMID: 27267714, PMCID: PMC5045514, DOI: 10.1210/en.2016-1233.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsBasic Helix-Loop-Helix Transcription FactorsCarcinoma, EndometrioidCase-Control StudiesCells, CulturedEndometrial HyperplasiaEndometrial NeoplasmsEndometriumFemaleFibroblast Growth FactorsGene Expression ProfilingHumansIndolesMiceMiddle AgedSelective Estrogen Receptor ModulatorsConceptsStromal cellsPostmenopausal womenHormone therapyEpithelial proliferationFGF18 expressionAntiproliferative effectsSelective estrogen receptor modulatorsHuman endometrial stromal cellsGrowth factorBZA/CEMenopausal hormone therapyEndometrial stromal cellsBreast cancer riskEstrogen receptor modulatorsCD1 female miceE74-like factor 5Normal proliferative endometriumParacrine growth factorPrimary stromal cellsTyrosine kinase receptor 2Fibroblast growth factorEndometrial hyperplasiaEndometrial proliferationEndometrial cancerEndometrial adenocarcinomaDifferential Expression of IR-A, IR-B and IGF-1R in Endometrial Physiology and Distinct Signature in Adenocarcinoma
Flannery CA, Saleh FL, Choe GH, Selen DJ, Kodaman PH, Kliman HJ, Wood TL, Taylor HS. Differential Expression of IR-A, IR-B and IGF-1R in Endometrial Physiology and Distinct Signature in Adenocarcinoma. The Journal Of Clinical Endocrinology & Metabolism 2016, 101: 2883-2891. PMID: 27088794, PMCID: PMC4929835, DOI: 10.1210/jc.2016-1795.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAntigens, CDCarcinoma, EndometrioidCells, CulturedEndometrial HyperplasiaEndometrial NeoplasmsEndometriumFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMenstrual CycleMiddle AgedProtein SubunitsReceptor, IGF Type 1Receptor, InsulinTranscriptomeConceptsIGF-1R expressionEndometrial hyperplasiaNormal endometriumEndometrial physiologySecretory phaseProliferative phaseIGF-1 receptor mRNAIR-B expressionNormal secretory phaseType 2 diabetesSex steroid treatmentEarly secretory phaseEarly proliferative phaseNormal proliferative phaseEndometrial proliferationEndometrioid adenocarcinomaComplex hyperplasiaEndometrial adenocarcinomaMass indexMenstrual cycleRisk factorsReceptor expressionIGF-1RMAIN OUTCOMEReceptor mRNA